Recombinant human erythropoietin, often referred to as EPO therapy, is preferred for patients with renal anemia. Patients with chronic renal failure who have reached the stage of uremia will have reduced EPO production due to kidney damage, which will also lead to reduced red blood cell production and cause anemia. At the same time, the accumulation of large amounts of metabolic waste in the body inhibits the hematopoietic function of bone marrow, accelerates the destruction of red blood cells, and affects the life span of red blood cells, leading to anemia. Patients with renal anemia often present with pallor, pale conjunctiva, and decreased hemoglobin, etc. Clinically, when blood loss and lack of hematopoietic material are excluded, hemoglobin <100g/L can be considered for starting treatment with recombinant human erythropoietin. Prior to treatment with recombinant human erythropoietin, iron supplementation is required, and ferrous succinate and ferrous sulfate can be administered orally. After iron supplementation, EPO is used, but specific dosage and usage are recommended under the guidance of a doctor, and the dosage should be adjusted according to the patient's hemoglobin level to standardize treatment and follow-up.